GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Operating Margin %

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Operating Margin % : 28.45% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Laboratorios Farmaceuticos Rovi's Operating Income for the three months ended in Dec. 2023 was €66.7 Mil. Laboratorios Farmaceuticos Rovi's Revenue for the three months ended in Dec. 2023 was €234.6 Mil. Therefore, Laboratorios Farmaceuticos Rovi's Operating Margin % for the quarter that ended in Dec. 2023 was 28.45%.

Good Sign:

Laboratorios Farmaceuticos Rovi SA operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Operating Margin % or its related term are showing as below:

XMAD:ROVI' s Operating Margin % Range Over the Past 10 Years
Min: 5.76   Med: 11.48   Max: 31.29
Current: 22.95


XMAD:ROVI's Operating Margin % is ranked better than
92.02% of 1027 companies
in the Biotechnology industry
Industry Median: -166.59 vs XMAD:ROVI: 22.95

Laboratorios Farmaceuticos Rovi's 5-Year Average Operating Margin % Growth Rate was 37.30% per year.

Laboratorios Farmaceuticos Rovi's Operating Income for the three months ended in Dec. 2023 was €66.7 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was €178.8 Mil.


Laboratorios Farmaceuticos Rovi Operating Margin % Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Operating Margin % Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.33 18.44 27.98 31.29 26.55

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.11 13.66 31.91 28.45 12.75

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Operating Margin %

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Operating Margin % falls into.



Laboratorios Farmaceuticos Rovi Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Laboratorios Farmaceuticos Rovi's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=220.254 / 829.509
=26.55 %

Laboratorios Farmaceuticos Rovi's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=66.745 / 234.636
=28.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Laboratorios Farmaceuticos Rovi Operating Margin % Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Headlines

From GuruFocus

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 02-03-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 44,145 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

27% Upside potentially in Rovi Corporation

By Bavneet Singh Nagpal bavinagpal 03-17-2015

TiVo Corporation to Announce First Quarter 2020 Results

By Business Wire Business Wire 04-23-2020

George Soros Buys Rovi Corp

By Kyle Ferguson Kyle Ferguson 09-08-2016

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 96,461 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011